Fady Daniel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fady Daniel has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Ali R. Chaitou
Division of Gastroenterology and Hepatology, Department of Internal Medicine, American University of Beirut Medical Center, PO Box: 11-023, Riad El Solh, Beirut, 1107 2020, Lebanon
5 shared publications- Hani Tamim
Department of Internal Medicine, Clinical Research Institute, American University of Beirut Medical Center
4 shared publications Mohamad Khalife
Division of General Surgery, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
4 shared publicationsRudy Mrad
Division of Gastroenterology and Hepatology, Department of Internal Medicine, American University of Beirut Medical Center, PO Box: 11-023, Riad El Solh, Beirut, 1107 2020, Lebanon
4 shared publicationsAla I. Sharara
Division of Gastroenterology and Hepatology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
3 shared publicationsBatoul Abdallah
Division of Gastroenterology and Hepatology, Department of Internal Medicine, American University of Beirut Medical Center, PO Box: 11-023, Riad El Solh, Beirut, 1107 2020, Lebanon
3 shared publications
Latest Publications
- 6 August 2026
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 49 (9) , 336-344
Identifying Patients at Risk for Immune Checkpoint Inhibitor-Induced Colitis: Evidence From a Real-World Oncology Cohort
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes across multiple malignancies but are associated with immune-related adverse events, including colitis. Although generally uncommon, ICI-induced colitis can lead to significant morbidity and treatment interruption, and data on its incidence and risk factors in the Middle East remain limited. We conducted a retrospective study of adult cancer patients treated with ICIs at a tertiary care center between December 2018 and March 2023. Clinical and treatment-related variables were collected, and univariable and multivariable logistic regression analyses were performed to identify predictors of colitis. Among 784 patients, 19 (2.4%) developed ICI-related colitis. Most cases were moderate to severe, and 57.9% required hospitalization, with a median length of stay of 7 days. All patients had advanced disease. Endoscopic evaluation, performed in 42.1% of patients, demonstrated heterogeneous disease distribution. ICI therapy was discontinued in 78.9% of patients and resumed in 36.8%. Corticosteroids were administered in 68.4% of patients, with a response rate of 92.3%; 1 patient required infliximab. One colitis-related death occurred. In univariable analysis, autoimmune disease, CTLA-4 inhibitor exposure, combination immunotherapy, and concurrent targeted therapy were significantly associated with colitis. In multivariable analysis, autoimmune disease ( OR =6.10, 95% CI: 1.55–24.08; P =0.010), combination immunotherapy ( OR =3.56, 95% CI: 1.09–11.63; P =0.035), and concurrent targeted therapy ( OR =3.88, 95% CI: 1.31–11.54; P =0.015) remained independent predictors. ICI-induced colitis is an uncommon but clinically meaningful toxicity, and recognizing patients at higher risk may help guide closer monitoring and improve clinical management.
- 6 August 2026
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 49 (9) , 336-344
Identifying Patients at Risk for Immune Checkpoint Inhibitor-Induced Colitis: Evidence From a Real-World Oncology Cohort
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes across multiple malignancies but are associated with immune-related adverse events, including colitis. Although generally uncommon, ICI-induced colitis can lead to significant morbidity and treatment interruption, and data on its incidence and risk factors in the Middle East remain limited. We conducted a retrospective study of adult cancer patients treated with ICIs at a tertiary care center between December 2018 and March 2023. Clinical and treatment-related variables were collected, and univariable and multivariable logistic regression analyses were performed to identify predictors of colitis. Among 784 patients, 19 (2.4%) developed ICI-related colitis. Most cases were moderate to severe, and 57.9% required hospitalization, with a median length of stay of 7 days. All patients had advanced disease. Endoscopic evaluation, performed in 42.1% of patients, demonstrated heterogeneous disease distribution. ICI therapy was discontinued in 78.9% of patients and resumed in 36.8%. Corticosteroids were administered in 68.4% of patients, with a response rate of 92.3%; 1 patient required infliximab. One colitis-related death occurred. In univariable analysis, autoimmune disease, CTLA-4 inhibitor exposure, combination immunotherapy, and concurrent targeted therapy were significantly associated with colitis. In multivariable analysis, autoimmune disease ( OR =6.10, 95% CI: 1.55–24.08; P =0.010), combination immunotherapy ( OR =3.56, 95% CI: 1.09–11.63; P =0.035), and concurrent targeted therapy ( OR =3.88, 95% CI: 1.31–11.54; P =0.015) remained independent predictors. ICI-induced colitis is an uncommon but clinically meaningful toxicity, and recognizing patients at higher risk may help guide closer monitoring and improve clinical management.
- 19 March 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (6) , 5086-5094
Association between postoperative Clostridioides difficile infection and outcomes following pancreatoduodenectomy for pancreatic cancer: a national cohort study
Clostridioides difficile infection (CDI) is a major healthcare-associated infection, but its impact after pancreatoduodenectomy (PD) for pancreatic cancer is unclear. This study assessed the incidence of CDI after PD for pancreatic cancer and evaluated preoperative factors associated with CDI, as well as the relationship between CDI and postoperative morbidity and mortality. A retrospective cohort study using the ACS-NSQIP database included patients who underwent PD for pancreatic head cancer. Patients were stratified by postoperative CDI, and univariate and multivariate logistic regression analyses identified risk factors and outcomes. Among 16,757 patients, 249 (1.5%) developed postoperative CDI. Multivariate analysis showed increasing age (OR 1.21, p = 0.02), lower body weight (OR 0.95, p = 0.01), and recent chemotherapy (OR 1.47, p = 0.01) as independent predictors of postoperative CDI. Postoperative CDI was significantly associated with increased odds of composite morbidity (OR 1.62, p = 0.02), sepsis (OR 1.62, p = 0.02), pancreatic fistula (OR 2.01, p < 0.001), delayed gastric emptying (OR 1.79, p = 0.001), organ-space surgical site infection (OR 1.99, p < 0.001), wound disruption (OR 3.91, p < 0.001), and septic shock (OR 2.24, p = 0.007). Although uncommon, CDI after PD was associated with increased morbidity in this cohort. Older patients, those with lower body weight, and patients receiving chemotherapy had higher odds of postoperative CDI and may benefit from close clinical monitoring and judicious antibiotic stewardship.
- 19 March 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (6) , 5086-5094
Association between postoperative Clostridioides difficile infection and outcomes following pancreatoduodenectomy for pancreatic cancer: a national cohort study
Clostridioides difficile infection (CDI) is a major healthcare-associated infection, but its impact after pancreatoduodenectomy (PD) for pancreatic cancer is unclear. This study assessed the incidence of CDI after PD for pancreatic cancer and evaluated preoperative factors associated with CDI, as well as the relationship between CDI and postoperative morbidity and mortality. A retrospective cohort study using the ACS-NSQIP database included patients who underwent PD for pancreatic head cancer. Patients were stratified by postoperative CDI, and univariate and multivariate logistic regression analyses identified risk factors and outcomes. Among 16,757 patients, 249 (1.5%) developed postoperative CDI. Multivariate analysis showed increasing age (OR 1.21, p = 0.02), lower body weight (OR 0.95, p = 0.01), and recent chemotherapy (OR 1.47, p = 0.01) as independent predictors of postoperative CDI. Postoperative CDI was significantly associated with increased odds of composite morbidity (OR 1.62, p = 0.02), sepsis (OR 1.62, p = 0.02), pancreatic fistula (OR 2.01, p < 0.001), delayed gastric emptying (OR 1.79, p = 0.001), organ-space surgical site infection (OR 1.99, p < 0.001), wound disruption (OR 3.91, p < 0.001), and septic shock (OR 2.24, p = 0.007). Although uncommon, CDI after PD was associated with increased morbidity in this cohort. Older patients, those with lower body weight, and patients receiving chemotherapy had higher odds of postoperative CDI and may benefit from close clinical monitoring and judicious antibiotic stewardship.
- 26 January 2026
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 27 (1) , 118-122
Accuracy of non-invasive indices for diagnosing hepatic steatosis compared to controlled attenuated parameter (CAP) in a Lebanese cohort
- 26 January 2026
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 27 (1) , 118-122
Accuracy of non-invasive indices for diagnosing hepatic steatosis compared to controlled attenuated parameter (CAP) in a Lebanese cohort
- Open Access
- 8 December 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 855
Correction: Compliance and yield of follow-up colonoscopy after a positive FIT in real-life practice: a university hospital experience
- 8 December 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 855
Open AccessCorrection: Compliance and yield of follow-up colonoscopy after a positive FIT in real-life practice: a university hospital experience
- Open Access
- 20 November 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 826
Compliance and yield of follow-up colonoscopy after a positive FIT in real-life practice: a university hospital experience
The fecal immunochemical test (FIT) is a diagnostic modality for colorectal cancer (CRC) screening, with the US Multisociety Task Force setting an 80% adherence benchmark for follow-up colonoscopy (FUC). Guidelines recommend that FITs be performed only in the context of CRC screening. Our study is a retrospective review of all patients with positive FIT records from 2018 to 2023. Patient characteristics, FIT ordering practices, and clinical settings were collected. The compliance rates with FUC, colonoscopy diagnostic yield, and adenoma detection were analyzed, and adherent and nonadherent patients were compared via univariate and logistic regression analyses. A total of 1424 patients had positive FIT results, with ages ranging between 18 and 92 years. Among the 1424 patients, 245 (17.2%) were < 45 years (group 1), 829 (52.9%) were 45–75 years (group 2), and 350 (24.6%) were > 75 years (group 3). In group 2, 241 (16.9%) tests were conducted for CRC screening. Seven hundred and three (49.3%) positive FIT tests, including tests for abdominal pain and anemia, were carried out for diagnostic purposes. Only 618 (43.3%) patients with positive FIT results underwent FUC, of whom 277 (44.8%) had adenomas and 28 (4.5%) were diagnosed with CRC. Bivariate analysis revealed that age, fewer comorbidities, prior colonoscopy, family history of CRC, diagnostic FIT, and outpatient setting increased FUC adherence. Multivariate analysis revealed that age and outpatient setting were predictive factors. Although FITs are used for CRC screening, our study found a discrepancy between guidelines and real-world practice. Compliance with FUC after a positive FIT is below the optimal range, with adherence decreasing with age.
- 20 November 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 826
Open AccessCompliance and yield of follow-up colonoscopy after a positive FIT in real-life practice: a university hospital experience
The fecal immunochemical test (FIT) is a diagnostic modality for colorectal cancer (CRC) screening, with the US Multisociety Task Force setting an 80% adherence benchmark for follow-up colonoscopy (FUC). Guidelines recommend that FITs be performed only in the context of CRC screening. Our study is a retrospective review of all patients with positive FIT records from 2018 to 2023. Patient characteristics, FIT ordering practices, and clinical settings were collected. The compliance rates with FUC, colonoscopy diagnostic yield, and adenoma detection were analyzed, and adherent and nonadherent patients were compared via univariate and logistic regression analyses. A total of 1424 patients had positive FIT results, with ages ranging between 18 and 92 years. Among the 1424 patients, 245 (17.2%) were < 45 years (group 1), 829 (52.9%) were 45–75 years (group 2), and 350 (24.6%) were > 75 years (group 3). In group 2, 241 (16.9%) tests were conducted for CRC screening. Seven hundred and three (49.3%) positive FIT tests, including tests for abdominal pain and anemia, were carried out for diagnostic purposes. Only 618 (43.3%) patients with positive FIT results underwent FUC, of whom 277 (44.8%) had adenomas and 28 (4.5%) were diagnosed with CRC. Bivariate analysis revealed that age, fewer comorbidities, prior colonoscopy, family history of CRC, diagnostic FIT, and outpatient setting increased FUC adherence. Multivariate analysis revealed that age and outpatient setting were predictive factors. Although FITs are used for CRC screening, our study found a discrepancy between guidelines and real-world practice. Compliance with FUC after a positive FIT is below the optimal range, with adherence decreasing with age.
- 31 October 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (2) , 955-964
MELD score is predictive of postoperative morbidity and mortality in patients with acute appendicitis undergoing appendectomy: ACS-NSQIP data analysis
Background The model for end-stage liver disease (MELD) score has been shown to be a valid predictive tool for postoperative risks across various types of surgeries, after initially being restricted to liver transplantation eligibility assessment in cirrhotic patients. Since appendectomy is one of the most common surgical procedures, our objective is to compare the impact of the three versions of the MELD score (1.0, 2.0, and 3.0) on the risk assessment of 30-day postoperative morbidity and mortality in patients undergoing appendectomy for acute appendicitis. Methods Data on patients undergoing appendectomy for acute appendicitis were collected from the ACS-NSQIP database from 2018 to 2022 using the Current Procedural Terminology (CPT) codes 44,950, 44,960, and 44,970. The different MELD scores and outcomes were compared using the Chi-square test. The outcomes measured included 30-day mortality, wound infection, cardiac, respiratory, urinary, and central nervous system complications, thromboembolism, sepsis, bleeding, return to the operating room, and composite morbidity. Results A total of 121,207 patients were included, with a mean age of 45.31 ± 17.89 years, of which 58,495 (48.3%) were females. The majority, 102,895 (90.7%) patients, underwent laparoscopic appendectomy, whereas 10,599 (9.3%) had open appendectomy. The overall 30-day surgical mortality was 0.5% (567/121,207), and postoperative sepsis was observed in 5.8% (7,063/121,207). All the MELD score versions significantly predicted the outcomes independently of the surgical approach (laparoscopic/open appendectomy, simple/complicated appendicitis) with means of 8.21 ± 2.81, 9.01 ± 3.39, and 9.21 ± 3.26 for MELD 1.0, MELD 2.0, and MELD 3.0 scores, respectively. MELD 3.0 score noticeably outperformed its predecessors regarding all the outcomes. Patients with a score ≥ 11 had a higher prevalence of postoperative complications. Conclusion The MELD score, in its three versions, is a valid tool for assessing 30-day morbidity and mortality risk following appendectomy for acute appendicitis. MELD 3.0, with a cutoff of 11, demonstrated superior predictive performance.
- 31 October 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (2) , 955-964
MELD score is predictive of postoperative morbidity and mortality in patients with acute appendicitis undergoing appendectomy: ACS-NSQIP data analysis
Background The model for end-stage liver disease (MELD) score has been shown to be a valid predictive tool for postoperative risks across various types of surgeries, after initially being restricted to liver transplantation eligibility assessment in cirrhotic patients. Since appendectomy is one of the most common surgical procedures, our objective is to compare the impact of the three versions of the MELD score (1.0, 2.0, and 3.0) on the risk assessment of 30-day postoperative morbidity and mortality in patients undergoing appendectomy for acute appendicitis. Methods Data on patients undergoing appendectomy for acute appendicitis were collected from the ACS-NSQIP database from 2018 to 2022 using the Current Procedural Terminology (CPT) codes 44,950, 44,960, and 44,970. The different MELD scores and outcomes were compared using the Chi-square test. The outcomes measured included 30-day mortality, wound infection, cardiac, respiratory, urinary, and central nervous system complications, thromboembolism, sepsis, bleeding, return to the operating room, and composite morbidity. Results A total of 121,207 patients were included, with a mean age of 45.31 ± 17.89 years, of which 58,495 (48.3%) were females. The majority, 102,895 (90.7%) patients, underwent laparoscopic appendectomy, whereas 10,599 (9.3%) had open appendectomy. The overall 30-day surgical mortality was 0.5% (567/121,207), and postoperative sepsis was observed in 5.8% (7,063/121,207). All the MELD score versions significantly predicted the outcomes independently of the surgical approach (laparoscopic/open appendectomy, simple/complicated appendicitis) with means of 8.21 ± 2.81, 9.01 ± 3.39, and 9.21 ± 3.26 for MELD 1.0, MELD 2.0, and MELD 3.0 scores, respectively. MELD 3.0 score noticeably outperformed its predecessors regarding all the outcomes. Patients with a score ≥ 11 had a higher prevalence of postoperative complications. Conclusion The MELD score, in its three versions, is a valid tool for assessing 30-day morbidity and mortality risk following appendectomy for acute appendicitis. MELD 3.0, with a cutoff of 11, demonstrated superior predictive performance.
- 15 May 2025
- Published by Springer Nature in Updates in Surgery
- p. 1-8
Impact of preoperative use of biologics on 30-day surgical morbidity and mortality in patients with Crohn’s disease undergoing ileocolectomy: National Surgical Quality Improvement Program database analysis
Preoperative use of biologics has been inconsistently reported to be associated with increased frequency of infectious and surgical anastomotic complications in inflammatory bowel disease patients. We aimed to evaluate the rates of 30-day postoperative morbidity and mortality in Crohn’s disease patients exposed preoperatively to biologics. Data were collected from the NSQIP (National Surgical Quality Improvement Program). Crohn’s disease patients undergoing open or laparoscopic ileocolectomy were identified using corresponding ICD 10 and CPT Codes from the NSQIP Participant Use Data File (PUF) for 2021. Patients were divided based on the preoperative use of biologics (group 1) and (group 2) for whom no biologics were used. A total of 910 patients (female n = 473; 52%, mean age of 42.3 ± 16.1) were included. The group 1 patients were significantly younger (40.30 years ± 15.33) than group 2 (43.58 years ± 16.8, p = 0.002) and had significantly slightly higher ASA III and IV scores (97.4% vs. 97.2%, p = 0.004). On the other hand, group 2 had a significantly higher prevalence of hypertension (20.2% vs. 12.8%, p = 0.003) and chronic obstructive pulmonary disease (2.6% vs. 0%, p = 0.001). No significant difference in remaining preoperative variables, surgical approach (laparoscopic vs. open), and comorbidities were found between the two groups. Only a significant prevalence of deep vein thrombosis and thromboembolism was found in patients exposed to biologics (1.1% vs. 0%, p = 0.027). Crohn’s disease patients undergoing ileocolectomy and exposed preoperatively to biologics did not show a significant increase in 30-day postoperative morbidity and mortality. The outcomes did not support the concept that biological agents increase septic complications.
- 15 May 2025
- Published by Springer Nature in Updates in Surgery
- p. 1-8
Impact of preoperative use of biologics on 30-day surgical morbidity and mortality in patients with Crohn’s disease undergoing ileocolectomy: National Surgical Quality Improvement Program database analysis
Preoperative use of biologics has been inconsistently reported to be associated with increased frequency of infectious and surgical anastomotic complications in inflammatory bowel disease patients. We aimed to evaluate the rates of 30-day postoperative morbidity and mortality in Crohn’s disease patients exposed preoperatively to biologics. Data were collected from the NSQIP (National Surgical Quality Improvement Program). Crohn’s disease patients undergoing open or laparoscopic ileocolectomy were identified using corresponding ICD 10 and CPT Codes from the NSQIP Participant Use Data File (PUF) for 2021. Patients were divided based on the preoperative use of biologics (group 1) and (group 2) for whom no biologics were used. A total of 910 patients (female n = 473; 52%, mean age of 42.3 ± 16.1) were included. The group 1 patients were significantly younger (40.30 years ± 15.33) than group 2 (43.58 years ± 16.8, p = 0.002) and had significantly slightly higher ASA III and IV scores (97.4% vs. 97.2%, p = 0.004). On the other hand, group 2 had a significantly higher prevalence of hypertension (20.2% vs. 12.8%, p = 0.003) and chronic obstructive pulmonary disease (2.6% vs. 0%, p = 0.001). No significant difference in remaining preoperative variables, surgical approach (laparoscopic vs. open), and comorbidities were found between the two groups. Only a significant prevalence of deep vein thrombosis and thromboembolism was found in patients exposed to biologics (1.1% vs. 0%, p = 0.027). Crohn’s disease patients undergoing ileocolectomy and exposed preoperatively to biologics did not show a significant increase in 30-day postoperative morbidity and mortality. The outcomes did not support the concept that biological agents increase septic complications.
- Open Access
- 14 January 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 31 (2) , 100783
Gastric polyps are not created equal: Know your enemy
Gastric polyps are commonly detected during upper gastrointestinal endoscopy. They are most often benign and rarely become malignant. Nevertheless, adequate knowledge, diagnostic modalities, and management strategies should be the endoscopist’s readily available “weapons” to defeat the potentially malignant “enemies”. This article sheds light on the valuable effort by Costa et al to generate a new classification system of gastric polyps as “good”, “bad”, and “ugly”. This comprehensive overview provides clinicians with a simplified decision-making process.
- 14 January 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 31 (2) , 100783
Open AccessGastric polyps are not created equal: Know your enemy
Gastric polyps are commonly detected during upper gastrointestinal endoscopy. They are most often benign and rarely become malignant. Nevertheless, adequate knowledge, diagnostic modalities, and management strategies should be the endoscopist’s readily available “weapons” to defeat the potentially malignant “enemies”. This article sheds light on the valuable effort by Costa et al to generate a new classification system of gastric polyps as “good”, “bad”, and “ugly”. This comprehensive overview provides clinicians with a simplified decision-making process.
- 16 July 2022
- Published by Elsevier in Journal of Voice
- Vol. 39 (1) , 206-211
Prevalence of Laryngopharyngeal Symptoms in Patients With Gastroesophageal Reflux Disease Refractory to Medical Therapy Undergoing Esophagogastroduodenoscopy
- 16 July 2022
- Published by Elsevier in Journal of Voice
- Vol. 39 (1) , 206-211
Prevalence of Laryngopharyngeal Symptoms in Patients With Gastroesophageal Reflux Disease Refractory to Medical Therapy Undergoing Esophagogastroduodenoscopy
- 19 June 2022
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 46 (7) , 101981
Impact of sedation type on adenoma detection rate by colonoscopy
- 19 June 2022
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 46 (7) , 101981
Impact of sedation type on adenoma detection rate by colonoscopy